Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Operating Leases (2023 - 2025)

bioAffinity Technologies (BIAF) has disclosed Operating Leases for 3 consecutive years, with $375139.0 as the latest value for Q3 2025.

  • On a quarterly basis, Operating Leases changed 0.0% to $375139.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $375139.0, a 0.0% change, with the full-year FY2024 number at $342098.0, up 20.88% from a year prior.
  • Operating Leases was $375139.0 for Q3 2025 at bioAffinity Technologies, up from $342098.0 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $375139.0 in Q3 2024 to a low of $283001.0 in Q4 2023.
  • A 3-year average of $339585.8 and a median of $348419.5 in 2024 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: rose 22.04% in 2024, then changed 0.0% in 2025.
  • bioAffinity Technologies' Operating Leases stood at $283001.0 in 2023, then grew by 20.88% to $342098.0 in 2024, then grew by 9.66% to $375139.0 in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Operating Leases are $375139.0 (Q3 2025), $342098.0 (Q4 2024), and $375139.0 (Q3 2024).